Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo ER in Endocrine Refractory Metastatic Breast Cancer

NCT02409316 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT02409316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02409316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo ER in Endocrine Refractory Metastatic Breast Cancer
Lead sponsor
University of Pennsylvania
Phase
Phase 2
Overall status
Terminated
Start date
October 15, 2015
Completion date
August 1, 2025
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm, estrogen receptor positive breast cancer, metastatic breast cancer